Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 11/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269625 | 1.00 | CTSD (0.40) | CTSDHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL2872653 | 1.00 | CTSD (0.40) | CTSDHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL9182647 | 0.83 | KEAP1 (0.41) | CTSDHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL18872524 | 0.81 | CTSD (0.42) | CTSDHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL23754416 | 0.80 | CTSD (0.40) | CTSD | |
| SCHEMBL31509493 | 0.80 | CTSD (0.40) | CTSD | |
| SCHEMBL13250134 | 0.80 | CTSD (0.40) | CTSD | |
| SCHEMBL18056086 | 0.79 | CTSD (0.33) | CTSD | |
| SCHEMBL8135687 | 0.78 | KEAP1 (0.31) | — | |
| SCHEMBL4457510 | 0.78 | PIK3CD (0.37) | CTSDHDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897833-B1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250042878-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-02-06 | — | — | US | disclosed |
| US-12060346-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-08-13 | — | — | US | disclosed |
| CN-113453760-B | APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| CN-116925924-A | England thistle endophytic fungi Bartalinia pondoensis wz03 and application thereof | 华侨大学 | 2023-10-24 | — | — | CN | disclosed |
| CN-116925924-A | England thistle endophytic fungi Bartalinia pondoensis wz03 and application thereof | 华侨大学 | 2023-10-24 | — | — | CN | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-20060014755-A1 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | MERCK SHARP & DOHME CORP. | 2006-01-19 | — | — | US | disclosed |
| EP-1578735-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | Pfizer Limited (GB) | 2005-09-28 | — | — | EP | disclosed |
| US-6903102-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | disclosed |
| US-20040132736-A1 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION | 2004-07-08 | — | — | US | disclosed |
| WO-2004056787-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| EP-1423381-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | Schering Corporation (US) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003022835-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-1228066-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032646-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | CTSD 411/4885HDAC1 3717/4885HDAC3 4721/4885 |
| US-12060346-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, SAAL1 | CTSD 411/4885HDAC1 3717/4885HDAC3 4721/4885 |
| US-20040132736-A1 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | HSD17B3, HSD17B1, HSD17B11 | CTSD 2136/4885HDAC1 446/4885HDAC3 844/4885 |
| US-20250042878-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | CTSD 411/4885HDAC1 3717/4885HDAC3 4721/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | CTSD 699/4885HDAC1 44/4885HDAC3 95/4885 |
| US-20060014755-A1 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | HSD17B3, HSD17B1, HSD17B11 | CTSD 2201/4885HDAC1 514/4885HDAC3 820/4885 |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | MME, ECE1, ECE2 | CTSD 384/4885HDAC1 1760/4885HDAC3 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.